GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (FRA:BJ9) » Definitions » Cyclically Adjusted PB Ratio

Benitec Biopharma (FRA:BJ9) Cyclically Adjusted PB Ratio : (As of Jun. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Benitec Biopharma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Benitec Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Benitec Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Cyclically Adjusted PB Ratio Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 0.03

Competitive Comparison of Benitec Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted PB Ratio falls into.



Benitec Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Benitec Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Benitec Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.033/131.7762*131.7762
=0.033

Current CPI (Mar. 2024) = 131.7762.

Benitec Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.000 98.326 0.000
201406 0.142 100.560 0.186
201412 0.168 99.070 0.223
201503 0.000 99.621 0.000
201506 0.139 100.684 0.182
201509 0.000 100.392 0.000
201512 0.123 99.792 0.162
201603 0.115 100.470 0.151
201606 0.085 101.688 0.110
201609 0.091 101.861 0.118
201612 0.071 101.863 0.092
201703 0.083 102.862 0.106
201706 0.071 103.349 0.091
201709 0.060 104.136 0.076
201712 0.051 104.011 0.065
201803 0.040 105.290 0.050
201806 0.046 106.317 0.057
201809 0.000 106.507 0.000
201812 0.068 105.998 0.085
201903 0.000 107.251 0.000
201906 0.057 108.070 0.070
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.028 108.767 0.034
202009 0.020 109.815 0.024
202012 0.037 109.897 0.044
202103 0.029 111.754 0.034
202106 0.052 114.631 0.060
202109 0.041 115.734 0.047
202112 0.030 117.630 0.034
202203 0.021 121.301 0.023
202206 0.008 125.017 0.008
202209 0.046 125.227 0.048
202212 0.026 125.222 0.027
202303 0.014 127.348 0.014
202306 0.001 128.729 0.001
202309 0.065 129.860 0.066
202312 0.044 129.419 0.045
202403 0.033 131.776 0.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Benitec Biopharma  (FRA:BJ9) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Benitec Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (FRA:BJ9) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (FRA:BJ9) Headlines

No Headlines